Oxygen-ozone immunoceutical therapy in COVID-19 outbreak: facts and figures

Ricevuti, Giovanni; Franzini, Marianno; Valdenassi, Luigi

doi:10.4081/ozone.2020.9014

Cited by 24 publications

(29 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Studies have also reported the efficacy and safety of ozone administration on patients of human immunodeficiency virus (HIV), hepatitis C, Ebola, influenza. 3,5,6 As a new immunotherapy and an inexpensive, safe modality, ozone therapy has its rationality in the treatment of COVID-19 patients, 7,8 which was confirmed by our preliminary observational results.…”

Section: Discussionsupporting

confidence: 54%

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19

Zheng

Dong

2020

Journal of Medical Virology

View full text Add to dashboard Cite

To the Editor, No therapeutics has been proven effective for treatment of coronavirus disease 2019 (COVID-19). 1,2 China has explored important clinical trials on a host of possible effective treatment options including ozone therapy. We introduced our experience in treating two confirmed cases by ozone therapy-major autohemotherapy (MAH). 3 After the written informed consent was obtained, MAH was given to patients once daily for 7 consecutive days. Each time, 100 mL of venous blood was collected and mixed with O 3 gas at the 1:1 ratio of oxygen-ozone to blood volume, with the final concentration of oxygen-ozone being 20 μg/mL. The clinical study was approved by the Clinical Research Ethics Committee of Renmin Hospital of Wuhan University (WDRY2020-K020). CASE 1 A male of 53-year-old was admitted to Renmin Hospital of Wuhan University on 20 February 2020 due to mild fever and dyspnea for 7 days, accompanied by headache, runny nose, fatigue, and loss of appetite. On admission, he presented a clear consciousness with a body temperature of 37.5℃. Chest computed tomography (CT) imaging on 19 February 2020 revealed multiple small patchy shadows, linear interstitial changes, and consolidation in both lungs. He was confirmed COVID-19 on 21 February 2020 Lymphopenia, elevated C-reactive protein and interleukin 6, mild hypoxemia were noted in laboratory tests.

show abstract

Section: Discussionsupporting

confidence: 54%

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19

Zheng

Dong

2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…According to literature data, exposure of bacteria, spores and viruses to ozone for only a few minutes causes inactivation [25][26] . Studies by Ricevudi et al 27 proposed oxygen-ozone treatment as a new immunotherapeutic treatment method for the viral agent COVID-19 causing this pandemic and that patients with COVID-19 using this in combination with other treatment methods would benefit from the assisting and synergic effects of ozone therapy. Again, as stated by Ricevudi et al 27 the need for more studies is clear.…”

Section: ■ Discussionmentioning

confidence: 99%

“…Studies by Ricevudi et al 27 proposed oxygen-ozone treatment as a new immunotherapeutic treatment method for the viral agent COVID-19 causing this pandemic and that patients with COVID-19 using this in combination with other treatment methods would benefit from the assisting and synergic effects of ozone therapy. Again, as stated by Ricevudi et al 27 the need for more studies is clear. The bactericidal effect of ozone is linked to attacking the biological material in microorganisms through the oxidation pathway.…”

Section: ■ Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary effects of ozone therapy at different doses combined with antibioticotherapy in experimental sepsis model

et al. 2020

View full text Add to dashboard Cite

This experimental sepsis model created with Escherichia coli aimed to investigate the histopathological effects of two different doses of ozone combined with antibiotherapy on lung tissue. Methods: Rats were divided into 5 groups. Then sepsis was induced intraperitoneally in the first 4 groups. The 1 st group was treated with cefepime, the 2 nd and 3 rd groups were treated with cefepime combined with ozone at a dose of 0.6 mg/kg and 1.1 mg/kg. Lung tissue sections were stained with hematoxylin-eosin and assessed under light microscope and scored between 0-4 in terms of histopathological findings. Results: In the comparisons between Group 1 and Group 4 in terms of cellular damage (p=0.030), inflammation (p=0.000) and overall score (p=0.007), statistically significant positive effects were observed in favor of Group 1. In the comparisons of Groups 2 and 3 with Group 4, only positive effects were observed in terms of inflammation (p=0.020, p=0.012, respectively). Conclusion: Although negative histopathological effects of ozone on tissue injury were detected, it was noteworthy that the increase in the ozone dose reduced the number of damaged parameters.

show abstract

“…Another important effect of O 3 -AHT in the COVID-19 therapeutical context is the down-regulation action of pyrin domain-containing protein 3 (NLRP3) inflammasome, which is known to play a crucial part in the initiation and continuance of inflammation in various diseases [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience

Tascini¹,

Sermann

Pagotto³

et al. 2020

Intern Emerg Med

View full text Add to dashboard Cite

The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not confirmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone (O 2 /O 3 ) gaseous mixture as adjuvant therapy. In Udine University Hospital (Italy) we performed a case–control study involving hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. Clinical presentations are based upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU—Società Italiana di Medicina di Emergenza-Urgenza) and patients that met criteria of phenotypes 2 to 4 were treated with best available therapy (BAT), with or without O 3 -autohemotherapy. 60 patients were enrolled in the study: 30 patients treated with BAT and O 2 /O 3 mixture, as adjuvant therapy and 30 controls treated with BAT only. In the group treated with O 3 -autohemotherapy plus BAT, patients were younger but with more severe clinical phenotypes. A decrease of SIMEU clinical phenotypes was observed (2.70 ± 0.67 vs. 2.35 ± 0.88, p = 0.002) in all patients during hospitalization but this clinical improvement was statistically significant only in O 3 -treated patients (2.87 ± 0.78 vs. 2.27 ± 0.83, p < 0.001), differently to the control group (2.53 ± 0.51 vs. 2.43 ± 0.93, p = 0.522). No adverse events were observed associated with the application of O 2 /O 3 gaseous mixture. O 2 /O 3 therapy as adjuvant therapy could be useful in mild to moderate pneumonia due to SARS-CoV-2. Randomized prospective study is ongoing [Clinical Trials.gov ID: Z7C2CA5837].

show abstract

Oxygen-ozone immunoceutical therapy in COVID-19 outbreak: facts and figures

Cited by 24 publications

References 16 publications

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19

Pulmonary effects of ozone therapy at different doses combined with antibioticotherapy in experimental sepsis model

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience

Contact Info

Product

Resources

About